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Background: Matrix-associated autologous chondrocyte implantation (MACI) is a further development of the original autologous
chondrocyte implantation periosteal flap technique (ACI-P) for the treatment of articular cartilage defects.
Purpose: We aimed to establish whether MACI or ACI-P provides superior long-term outcomes in terms of patient satisfaction,
clinical assessment, and magnetic resonance imaging (MRI) evaluation.
Study Design: Randomized controlled trial; Level of evidence, 2.
Methods: A total of 21 patients with cartilage defects at the femoral condyle were randomized to MACI (n = 11) or ACI-P (n = 10)
between the years 2004 and 2006. Patients were assessed for subjective International Knee Documentation Committee (IKDC)
score, Lysholm and Gillquist score, Tegner Activity Score, and 36-Item Short Form Health Survey (SF-36) preoperatively (T0),
at 1 and 2 years postoperatively (T1, T2), and at the final follow-up 8 to 11 years after surgery (T3). Onset of osteoarthritis was
determined using the Kellgren-Lawrence score and Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART)
score, and delayed gadolinium-enhanced MRI of cartilage was used to evaluate the cartilage. Adverse events were recorded
to assess safety.
Results: There were 16 patients (MACI, n = 9; ACI-P, n = 7) who were reassessed on average 9.6 years after surgery (76% follow-
up rate). The Lysholm and Gillquist score improved in both groups after surgery and remained elevated but reached statistical
significance only in ACI-P at T1 and T2. IKDC scores increased significantly at all postoperative evaluation time points in ACI-
P. In MACI, IKDC scores showed a significant increase at T1 and T3 when compared with T0. In the majority of the patients
(10/16; MACI, 5/9; ACI-P, 5/7) a complete defect filling was present at the final follow-up as shown by the MOCART score,
and 1 patient in the ACI-P group displayed hypertrophy of the repair tissue, which represents 6% of the whole study group
and 14.3% of the ACI-P group. Besides higher SF-36 vitality scores in ACI-P at T3, no significant differences were seen in clinical
scores and MRI scores between the 2 methods at any time point. Revision rate was 33.3% in MACI and 28.6% in ACI-P at the last
follow-up.
Conclusion: Our long-term results suggest that first- and third-generation ACI methods are equally effective treatments for iso-
lated full-thickness cartilage defects of the knee. With the number of participants available, no significant difference was noted
between MACI and ACI-P at any time point. Interpretation of our data has to be performed with caution due to the small sample
size, which was further limited by a loss to follow-up of 24%.
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Full-thickness cartilage lesions present clinically with pain
and significant activity impairment and may progress to
degenerative osteoarthritis. The treatment of these lesions
has posed a difficult challenge since the dawn of surgery.6
To address the limited intrinsic healing potential of articu-
lar hyaline cartilage, the first procedure of autologous
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chondrocyte implantation (ACI) was introduced in 1987,11
and its results in humans were described by Brittberg et al4
in 1994. It was the first biological approach using cell trans-
plantation with the aim of providing hyaline-type repair tis-
sue to the defect area. The first generation of ACI with
a periosteum cover (ACI-P) showed good midterm and long-
term results over a follow-up period of more than 10
years.23,26,33 Even though these data strongly support the
use of ACI-P as an effective treatment in patients with chon-
dral and osteochondral lesions of the knee joint, the method
has been considered problematic due to the use of a periosteal
flap, the increased morbidity by a separate tibial incision with
resulting longer operation time, and potential graft hypertro-
phy.15,32 Further concerns were the uneven distribution of
chondrocytes within the defect and the potential risks of cell
leakage. Thus, the original technique underwent several mod-
ifications aimed at improving clinical outcome and reducing
complication rates. As a result, use of a synthetic type I/III col-
lagen cover (second-generation ACI)10,17 and use of 3-dimen-
sional matrix systems (third-generation ACI or matrix-
associated autologous chondrocyte implantation [MACI])
were introduced.1,8,16 In comparison with first- and second-
generation ACI, MACI simplifies the surgical treatment and
reduces the number of incisions and the duration of surgery.22
ACI-P and MACI have been proven to be durable and
effective treatment options for cartilage defects in the
knee. Both techniques provide good short- and long-term
results in the majority of patients.8,16 Even though there
is a trend toward applying later-generation ACI and con-
sidering this to be the superior technique over ACI-P, the
scientific support for this choice is rather weak. Only a lim-
ited number of studies with high evidence levels have eval-
uated the clinical results of these techniques in
a randomized clinical trial.20,24,27,40
A previously published level 1 study compared MACI
versus ACI-P with a short-term follow-up of 24 months.40
No differences were observed in the efficacy between the 2
techniques at 12 and 24 months after surgery regarding
International Knee Documentation Committee (IKDC)
score, Tegner Activity Score, and 36-Item Short Form
Health Survey (SF-36) score; however, better efficacy
was observed in the ACI-P group according to the
Lysholm and Gillquist score at 12 months after surgery.
Since the major interest is to determine whether later-
generation ACI results in better long-term outcomes in
comparison with the first-generation ACI, we decided to
present an extension of this study with a comprehensive
clinical and radiological follow-up of 8 to 11 years after
surgery. This is, to our best knowledge, the first random-
ized prospective clinical trial to present long-term results
of ACI-P versus MACI by evaluating the patients in terms
of clinical assessment, patient satisfaction, and radio-
graphical evaluation.
METHODS
Study Design and Data Collection
This is a follow-up study on the prospective randomized
controlled trial (parallel trial design, allocation ratio 1:1)
published by our group in 2010.40 For this study, we con-
tacted all initially included patients who had symptomatic
full-thickness chondral defects of the femur and were trea-
ted with ACI with periosteum or matrix by 2 experienced
surgeons at our clinic between March 2004 and June
2006; these patients were rescheduled for clinical, radio-
graphic, and magnetic resonance imaging (MRI) examina-
tion between September 2014 and March 2016. The
inclusion criteria were patients (16-50 years of age) with
isolated cartilage defects (2.5-6 cm2) localized at the medial
or lateral femoral condyle detected by MRI and verified
with arthroscopy. Exclusion criteria were extended carti-
lage erosion, restricted mobility, corresponding cartilage
defects higher than grade II according to Outerbridge30
(ie, ‘‘kissing’’ defects or defects on the opposing surface),
extended meniscal defect (meniscal resection .1/3),
untreated cruciate or collateral ligament laxity, untreated
varus or valgus alignment more than 5, obesity, inflam-
mation, procedures in the respective knee (eg, microfrac-
ture or osteochondral autograft) less than 1 year ago,
hyaluronan injection less than 6 months ago, and cortico-
steroid injection less than 3 months ago. Complete clinical
data were available from the preoperative evaluation (T0)
and at 12 months after the operation (T1), 24 months after
the operation (T2), and the last follow-up (T3) from 16
patients. At these time points, patients had subjectively
rated their overall condition using validated scoring sys-
tems as described below. At the final follow-up, MRI was
performed on all 16 patients. Sociodemographic and occu-
pational parameters and defect characteristics were
recorded and are presented in Table 1.
Between the assessment time points, additional infor-
mation had been recorded on follow-up questionnaires,
including data on adverse events, treatment failures, and
operations after ACI. The local ethics committee approved
the study (No. 127/2004), and written informed consent
forms were received from all patients. The study was per-
formed in accordance with the German Medical Associa-
tion’s professional code of conduct and with the
Declaration of Helsinki in the 1996 version39 and according
to the German Data Protection Act of 1990.25
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Surgical Procedure and Rehabilitation
The surgical technique and clinical rehabilitation were
described in detail in the initial publication.40
Clinical and Radiological Evaluation
Clinical outcome parameters were ascertained by means of
questionnaires and clinical assessment. The postoperative
changes in subjective knee function were assessed by the
IKDC score12 at 12 months, 24 months, and the last
follow-up. The objective IKDC score was assessed at the
final follow-up. In addition, the visual analog scale (VAS)
for pain at the last follow-up was analyzed in an explor-
atory fashion. Postoperative changes in health-related
quality of life (SF-36),38 physical activity (Tegner Activity
Score),36 and knee functionality (Lysholm and Gillquist
score)19 were measured at the first visit and at 12 months,
24 months, and the last follow-up. All the instruments we
used are valid and reliable and are widely used in medical
outcome studies. All recorded data underwent further com-
puter-assisted plausibility checks. All data sets, after nec-
essary admissible corrections, in accordance with the
instructions described by Moradi et al,23 were subse-
quently prepared for statistical analysis. At the last
follow-up, the radiographs were classified according to
the Kellgren-Lawrence score to categorize the presence of
osteoarthritis.13
MRI Evaluation
We performed 2 different analyses, first using morpholog-
ical MRI sequences to determine the MOCART (Magnetic
Resonance Observation of Cartilage Repair Tissue) score
and second using the delayed gadolinium-enhanced MRI
of cartilage (dGEMRIC) technique to evaluate alterations
of the T1 relaxation time of the repair cartilage and hence
the content of glycosaminoglycans.5 Details are as follows:
MRI was performed on a 70-cm, open-bore, 3.0-T whole-
body scanner (Magnetom Verio; Siemens Healthineers),
equipped with an 18-channel total-imaging matrix (TIM
[102 3 18] configuration) in combination with a dedicated
15-channel knee coil. Standard morphological and func-
tional MRI was performed during the same session. During
the period between September 2014 and March 2016,
a total of 16 patients underwent a 3.0-T MRI examination
according to the study protocol, which included 4 morpho-
logical sequences: coronal proton density–weighted turbo
spin-echo (with and without fat saturation), sagittal proton
density, and sagittal T1 spin-echo. To obtain the dGEMRIC
images of 16 patients, we used a protocol similar to that
suggested by Rehnitz et al.34 We also used a 3D T1-
weighted VIBE sequence (repetition time/echo time, 15/
2.5 ms; voxel size, 0.4 3 0.4 3 3 mm3; acquisition time,
3.18 minutes; field of view, 159 3 159 mm; imaging
matrix, 384 3 384; echo train lengths, 1) with 2 excitation
flip angles (5 and 26), which was performed before and
after intravenous administration of a double dose of
TABLE 1
Characteristics of the Study Populationa
MACI ACI-P P Value
Total patients, n (%) 9 (56) 7 (44)
Sex, n (%) .017 (x2 test)
Male 4 (44.4) 7 (100)
Female 5 (55.6) 0 (0)
Age at surgery, y 30.4 6 6.8 28.8 6 9.1 .175 (t test)
31 (17-40) 34 (16-39)
Body mass index, kg/m2
Before surgery 23.32 6 1.15 25.41 6 2.55 .043 (t test)
23.6 (21.2-25) 25.9 (21.6-28.7)
After surgery 24.9 6 0.8 26.6 6 1.2 .390 (t test)
24.6 (21.2-29.3) 27.5 (22.1-30.1)
Follow-up time, y 9.6 6 0.9 8.6 6 0.8 .764 (t test)
10.3 (8-11) 9.3 (8-10)
Age at final follow-up, y 40.44 6 2.3 38.43 6 3.4 .199 (t test)
41 (27-51) 43 (26-48)
Preinjury sports activity level, n (%) .670 (x2 test)
Competitive 1 (11.1) 2 (28.6)
Well-trained 2 (22.2) 1 (14.3)
Occasionally 5 (55.6) 4 (57.1)
No sports 1 (11.1) 0 (0)
No. of previous surgeries 2.22 6 0.4 1.86 6 0.03 .693 (Mann-Whitney test)
2 (1-5) 2 (1-3)
No. of surgeries after ACI 0.33 6 0.17 0.29 6 0.19 .844 (Mann-Whitney test)
0 (0-1) 0 (0-1)
aData are presented as mean 6 SD with median (range) unless otherwise indicated. ACI, autologous chondrocyte implantation; ACI-P,
ACI with periosteum; MACI, matrix-associated autologous chondrocyte implantation. Unpaired t test, x2 test, and Mann-Whitney U test
were used. Boldface indicates satistical significance at P\ .05.
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gadopentetate dimeglumine (0.2 mmol/kg Gd-DTPA, Mag-
nevist; Bayer Vital). After administration of Gd-DTPA, the
participants walked for 15 minutes, and after 90 minutes
the postcontrast T1-mapping sequences were performed.
The resulting T1 values are referred to as the dGEMRIC
values.
Image Analysis
The morphological image analysis was performed on our
picture archiving and communication system (Centricity
PACS, version 3.0.4; GE Healthcare Integrated IT Solu-
tions). Both radiological reviewers (C.R. and his colleague)
were blinded to the study groups, and evaluation was per-
formed in consensus. The dGEMRIC (T1) maps were ana-
lyzed by use of the workstation Leonardo (Siemens
Healthineers). The morphological sequences were used to
determine the MOCART score.21 Because we did not use
the entirely same sequences as in the original publication,
the results are referred to as a modified or adapted 2-dimen-
sional MOCART score, which has been presented in a simi-
lar way in another study.18 To analyze the functional
dGEMRIC images, a region of interest (ROI) analysis was
applied. One ROI was placed in the repair cartilage, and
another ROI was placed in the normal-appearing adjacent
cartilage, with a minimum distance of 1 cm, and the result-
ing T1 relaxation times were compared.
Data Management and Statistical Analysis
The IKDC score was used as the primary outcome param-
eter for confirmatory statistics. At the time of study initia-
tion,40 the sample size estimation for the main outcome
parameter was based on a 2-tailed test problem for
2-sample Student t test. Power was set to 80% and the
error to 5%. Using an internet-based tool for sample size
estimation, we estimated a difference between the means
with an SD of 5 points and 3.5 points, respectively. This
resulted in a minimal sample size of 8 patients per group.
The estimation was adjusted to 10 patients per group for
possible preliminary dropouts.40 Our post hoc power anal-
ysis using the G* Power 3.1 tool (introduced by Faul et al7)
for 2-sample Wilcoxon-Mann-Whitney test showed an
effect size of 0.69 and a power of 0.24. Randomization
was performed through use of an internet-based computer
software, assigning patients by chance to either ACI-P or
MACI to ensure consistency of observation as described
by Zeifang et al.40
A descriptive analysis of the patient data was performed
to investigate whether the survey groups were homoge-
neous. Continuous baseline variables were presented by
mean, standard deviation, median, and range. The differ-
ence between continuous baseline variables was calculated
either by t test or by Mann-Whitney U test, if the variables
were not normally distributed. Categorical baseline varia-
bles were summarized according to frequencies and per-
centages. The x2 test was used to analyze the proportions
of categorical variables. For nonparametric time-
dependent variables, we used the Friedman and Wilcoxon
tests. Comparisons between subgroups of patients were
performed with the Mann-Whitney U test for nonparamet-
ric data. All reported P values are 2-tailed. P \ .05 was
considered statistically significant. A Bonferroni correction
was performed to prevent type I error caused by multiple
testing. All statistical analyses were performed by use of
SPPS software (SPSS version 23; IBM Corp).
RESULTS
Description of Study Population
In the initial study, 21 patients were treated with ACI
(MACI, n = 11; ACI-P, n = 10) with a sex ratio of 6 men
and 5 women in the MACI group and 10 men in the ACI-
P group.40 A total of 16 patients (MACI, n = 9; ACI-P,
n = 7) were recruited for reassessment for the current
study, representing a follow-up rate of 76%. The 2 groups
showed a significant difference regarding sex ratio (P =
.017). Body mass index before surgery showed a significant
difference between groups (MACI, 23.32 6 1.15; ACI-P,
25.41 6 2.55; P = .043). All patients completed at least 8
years of follow-up, with a mean follow-up of 9.6 6 0.9 years
in the MACI group and 8.6 6 0.8 years in the ACI-P group.
Detailed descriptions of study population are given in
Tables 1 and 2.
Clinical Evaluation
The therapy outcome was assessed by clinical scores, as
shown in Tables 3 and 4. Evaluation of the clinical data
in a categorical fashion is shown in Appendix Table A1
(available in the online version of this article).
The Tegner Activity Score in the ACI-P group increased
continuously to the final follow-up (T0:T3; P = .017), and
each increase proved to be significant when compared
with the preoperative status. Categorical evaluation in
the ACI-P group showed that 85.2% of patients were rated
as poor to fair at T0, which improved to 72.2% being rated
as good to excellent at T2. At the final follow-up, 57.4%
were still rated as good to excellent. In the MACI group,
no significant differences were seen over time. The MACI
group started with slightly higher scores, which decreased
over T1 and T2 and improved marginally at T3. The MACI
group started with 66.7% being rated as poor to fair, and
this remained unchanged at all evaluation time points.
One patient (11.1%) was rated as excellent in the MACI
group at T0, and this category improved to 22.2% at T3.
No significant difference was observed between the study
groups at any time point.
The Lysholm and Gillquist score improved significantly
from preoperative status to the first follow-up and
remained significantly elevated at 24 months postopera-
tively in the ACI-P group. In the MACI group, the Lysholm
and Gillquist score peaked at the first follow-up and
decreased until the last follow-up, but changes were not
significant. Categorical evaluation revealed that in the
ACI-P group, all patients were categorized as poor to fair
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at T0. Already at the 12-month follow-up (T1), 85.2% were
rated as excellent with a decrease to 71.4% at T2. At the
final follow-up (T3), 72.2% were still categorized as good
to excellent. In the MACI group, 66.7% were rated as
poor at T0, which decreased at T1 to 33.3% but reached pre-
operative levels at T3. No significant differences were seen
between the study groups at any time point.
The subjective IKDC score increased significantly from
baseline to the postoperative time points in the ACI-P
group. In the MACI group, subjective IKDC scores showed
a significant increase at T1 and T3 when compared with
preoperative status (T0:T1, P = .011; T0:T3, P = .021).
Whereas the majority of patients started with poor subjec-
tive IKDC scores at T0 (ACI-P, 100%; MACI, 89.9%), the
percentages of poor ratings decreased to 66.7% in MACI
and 14.8% in ACI-P. No significant differences were seen
in subjective IKDC scores between the 2 ACI methods at
any follow-up time, as shown in Table 3.
The objective IKDC scores at the final follow-up did not
show any significant differences between the 2 groups
(Appendix Table A2, available online). At the final follow-
up, the pain level was assessed by VAS, which showed no
significant difference between the 2 groups (P = .589).
SF-36 and Subscales
Scores for physical health increased significantly from
baseline to all postoperative time points in the ACI-P
group. The MACI group showed a significant increase at
T2 and T3 when compared with preoperative status
(T0:T2, P = .021; T0:T3, P = .008).
Mental health scores remained unchanged in the MACI
group until the 24-month follow-up and increased slightly
from this value to the final follow-up. In the ACI-P group,
a slight significant increase was seen when comparing T0,
T1, and T2 to the final follow-up at T3.
The differences in subscales were as follows:
Physical functioning: Both groups demonstrated signifi-
cant improvements at each follow-up time in comparison
with the initial scores.
Physical role functioning: All patients showed significant
improvements at each follow-up time in comparison
with the preoperative status except in the ACI-P group
at T2.
Bodily pain: When ACI-P and MACI were evaluated
together, all follow-up scores were significantly higher
compared with T0. MACI showed a significant improve-
ment only at the last follow-up in comparison with T0.
In ACI-P, pain scores significantly improved from base-
line to the first and last follow-up.
Vitality: Scores did not show a significant improvement
from baseline to T1 and T2. Further, scores at the last
follow-up (T3) proved to be significantly higher compared
with T0. At T3, ACI-P showed significantly higher scores
than MACI (P = .049).
Social role functioning: Both groups showed a significant
improvement from baseline to the last follow-up. All
patients together also demonstrated significant improve-
ments at T0:T1 (P = .022), T0:T3 (P = .022), and T2:T3
(P = .046).
No significant changes were detected for the general
health, emotional role functioning, and mental health sub-
scales (Table 4).
TABLE 2
Defect Characteristics of the Study Populationa
MACI ACI-P P Value
Cause, n (%) .949 (x2 test)
Osteochondritis dissecans 5 (55.6) 3 (42.6)
Chondromalacia 4 (44.4) 4 (57.4)
Side, n (%) .131 (x2 test)
Right 6 (66.7) 2 (28.6)
Left 3 (33.3) 5 (71.4)
Defect localization, n (%) .362 (x2 test)
Medial femoral condyle 8 (88.9) 7 (100)
Lateral femoral condyle 1 (11.1) 0 (0)
Additional defects, n (%) .197 (x2 test)
Trochlea 1 (11.1) 0 (0)
Retropatellar 1 (11.1) 0 (0)
Defect size, cm2 4.27 6 0.2 4.08 6 0.44 .670 (t test)
4 (3-6) 4 (2.55-6)
Kellgren-Lawrence score (at the final follow-up), n .549 (x2 test)
0 1 2
1 5 4
2 0 0
3 2 1
4 1 0
aDefect size is expressed as mean 6 SD with median (range). ACI-P, autologous chondrocyte implantation with periosteum; MACI,
matrix-associated autologous chondrocyte implantation. Unpaired t test and x2 test were used. P\ .05 was considered significant.
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Subgroup Analysis
We corrected for the difference in sex distribution between
MACI and ACI-P by comparing only the male patients in
MACI with the ACI-P group. This did not alter the pattern
of clinical scores as described above. By comparing male
versus female in the MACI group, we further analyzed
whether clinical scores show a sex-specific pattern. No sig-
nificant differences were seen between male and female
patients at any time.
TABLE 3
Clinical Outcome at Different Time Pointsa
Preoperative 
(T0)
(n = 16)
12 Months 
Postoperative 
(T1)
(n = 16)
24 Months 
Postoperative 
(T2)
(n = 16)
Last Follow-up 
(T3)
(n = 16)
P Value  
(MACI)
P Value  
(ACI-P)
Tegner Activity Score T0:T1 P = .236
T0:T2 P = .341
T0:T3 P = .498
T1:T2 P = .713
T1:T3 P = .234
T2:T3 P = .357
T0:T1 P = .042
T0:T2 P = .042
T0:T3 P = .017b
T1:T2 P = .317
T1:T3 P = .581
T2:T3 P = .713
 MACI 4.6 r 2.7
4 (0-9)
3.9 r 2
4 (0-7)
4.2 r 3
3 (0-10)
4.9 r 2.3
4 (3-9)
 ACI-P 3.2 r 1.8
3 (2-7)
5.1 r 2.1
6 (3-8)
5.6 r 1.9
6 (3-8)
5.6 r 2.1
6 (3-9)
 P value at each time point 
  (MACI:ACI-P)
.119 .450 .255 .455
Lysholm and Gillquist score T0:T1 P = .314
T0:T2 P = .767
T0:T3 P = .374
T1:T2 P = .362
T1:T3 P t .999
T2:T3 P = .678
T0:T1 P = .018
T0:T2 P = .027
T0:T3 P = .063
T1:T2 P = .343
T1:T3 P = .249
T2:T3 P = .499
 MACI 65.1 r 21.6
65 (22-92)
88 r 29
88 (30-100)
78 r 29
78 (28-100)
72.4 r 16.4
66 (53-97)
 ACI-P 57.3 r 11.9
56 (40-75)
92 r 7.2
94 (77-98)
87 r 19.1
94 (46-100)
82 r 17.2
92 (50-95)
 P value at each time point 
  (MACI:ACI-P)
.265 .185 .137 .289
Subjective IKDC score T0:T1 P = .011b
T0:T2 P = .109
T0:T3 P = .021
T1:T2 P = .262
T1:T3 P = .593
T2:T3 P = .511
T0:T1 P = .018
T0:T2 P = .028
T0:T3 P = .018
T1:T2 P = .752
T1:T3 P = .917
T2:T3 P = .933
 MACI 46.1 r 2.5
37.4 (18.4-87.4)
69.1 r 23.6
75.9 (29.9-100)
65.1 r 29.4
66.7 (23-98.9)
70.4 r 19.3
65.5 (44.8-97.7)
 ACI-P 48.9 r 9.6
46 (37.9-64.4)
82 r 14.1
79.3 (64.4-98.9)
82.1 r 18.1
88.5 (52.9-100)
81.6 r 12.2
79.3 (64.4-97.7)
 P value at each time point  
  (MACI:ACI-P)
.396 .426 .315 .204
SF-36 Physical Health T0:T1 P = .051
T0:T2 P = .021
T0:T3 P = .008b
T1:T2 P = .635
T1:T3 P = .441
T2:T3 P = .594
T0:T1 P = .028
T0:T2 P = .043
T0:T3 P = .018
T1:T2 P = .753
T1:T3 P = .866
T2:T3 P = .612
 MACI 29.2 r 1.3
29.2 (27.8-32.1)
30.9 r 1.8
31.5 (28.4-32.5)
31 r 2.3
31.5 (27.1-33.5)
31.5 ±1.2
31.3 (30.1-33.3)
 ACI-P 30.3 r 1.2
30.6 (28.6-32.1)
31.9 r 1
31.8 (30.4-33.1)
32 r 1.1
32.2 (30.6-33.1)
32 r 0.7
32.1 (30.9-32.9)
 P value at each time point  
  (MACI:ACI-P)
.081 .340 .560 .368
SF-36 Mental Health T0:T1 P = .173
T0:T2 P = .066
T0:T3 P = .515
T1:T2 P = .208
T1:T3 P = .173
T2:T3 P = .028
T0:T1 P = .866
T0:T2 P = .310
T0:T3 P = .018
T1:T2 P = .753
T1:T3 P = .028
T2:T3 P = .028
 MACI 12.1 r 0.5
12.2 (11.4-13.2)
11.8 r 0.3
11.8 (11.1-12.2)
11.6 r 0.7
11.7 (10.5-12.7)
12.6 r 1.3
12 (10.9-1.6)
 ACI-P 11.9 r 0.6
12 (11-12.9)
11.9 r 0.4
11.9 (11.4-12.7)
11.7 r 0.5
11.6 (11-12.3)
13.6 r 1
13.5 (11.9-14.8)
 P value at each time point 
  (MACI:ACI-P)
.315 t.999 .832 .186
aScores are presented as mean r SD with median (range). ACI-P, autologous chondrocyte implantation with periosteum; IKDC, 
International Knee Documentation Committee; MACI, matrix-associated autologous chondrocyte implantation; SF-36, 36-Item Short 
Form Health Survey. Friedman, Wilcoxon matched-pairs, and Mann-Whitney U tests were used. Boldface indicates satistical significance 
at P < .05.
bStatistical assessments that remained significant after Bonferroni correction.
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TABLE 4
36-Item Short Form (SF-36) Health Survey Scalea
Preoperative  
(T0)
(n = 16)
12 Months 
Postoperative (T1)
(n = 16)
24 Months 
Postoperative 
(T2)
(n = 16)
Last Follow-up (T3)
(n = 16)
P Value 
(MACI)
P Value  
(ACI-P)
Physical functioning T0:T1 P = .044
T0:T2 P = .007b
T0:T3 P = .008b
T1:T2 P = .248
T1:T3 P = .106
T2:T3 P = .865
T0:T1 P = .018
T0:T2 P = .028
T0:T3 P = .028
T1:T2 P = .593
T1:T3 P = .892
T2:T3 P t .999
 MACI 36.11 r 24.85
35 (10-90)
67.22 r 27.96
80 (0-7)
72.78 r 32.70
90 (15-100)
79.44 r 20.07
90 (45-100)
 ACI-P 55 r 21.41
55 (30-85)
86.43 r 17.01
90 (60-100)
88.57 r 14.92
95 (65-100)
88.57 r 13.14
95 (70-100)
 P value at each time point 
  (MACI:ACI-P)
.112 .132 .383 .361
Physical role functioning T0:T1 P = .016b
T0:T2 P = .016b
T0:T3 P = .018
T1:T2 P t .999
T1:T3 P = .414
T2:T3 P = .414
T0:T1 P = .027
T0:T2 P = .101
T0:T3 P = .026
T1:T2 P t .999
T1:T3 P = .655
T2:T3 P = .655
 MACI 19.44 r 41.04
0 (–25 to 100)
69.44 r 46.40
100 (0-100)
69.44 r 46.40
100 (0-100)
80.56 r 34.86
100 (0-100)
 ACI-P 35.71 r 34.93
25 (0-100)
85.71 r 28.35
100 (25-100)
85.71 r 28.35
100 (25-100)
92.86 r 12.20
100 (75-100)
 P value at each time point 
  (MACI:ACI-P)
.222 .606 .606 .651
Bodily pain T0:T1 P = .069
T0:T2 P = .107
T0:T3 P = .021
T1:T2 P = .498
T1:T3 P = .528
T2:T3 P = .866
T0:T1 P = .063
T0:T2 P = .051
T0:T3 P = .043
T1:T2 P = .343
T1:T3 P t .999
T2:T3 P = .713
 MACI 39.78 r 28.74
31 (10-84)
68.56 r 25.29
74 (22-100)
63.44 r 35.39
62 (0-100)
63.67 r 25.52
61 (32-100)
 ACI-P 53 r 14.27
51 (31-74)
76.14 r 19.31
74 (51-100)
83 r 21.42
84 (41-100)
76.57 r 12.15
72 (62-100)
 P value at each time point 
  (MACI:ACI-P)
.242 .519 .276 .183
General health T0:T1 P = .767
T0:T2 P = .553
T0:T3 P = .345
T1:T2 P = .600
T1:T3 P = .722
T2:T3 P = .813
T0:T1 P = .216
T0:T2 P = .799
T0:T3 P = .394
T1:T2 P = .715
T1:T3 P = .833
T2:T3 P = .674
 MACI 69.44 r 20.80
67 (25-92)
72.11 r 24.96
77 (37-100)
69.67 r 26.92
72 (30-100)
74.33 r 19.89
87 (40-92)
 ACI-P 80.57 r 11.80
87 (67-97)
84.57 r 13.09
77 (67-100)
81.57 r 15.27
77 (65-100)
86 r 15.56
90 (52-97)
 P value at each time point 
  (MACI:ACI-P)
.183 .309 .457 .231
Vitality T0:T1 P = .660
T0:T2 P = .705
T0:T3 P = .008b
T1:T2 P = .334
T1:T3 P = .008b
T2:T3 P = .008b
T0:T1 P = .187
T0:T2 P = .416
T0:T3 P = .018
T1:T2 P = .891
T1:T3 P = .018
T2:T3 P = .018
 MACI 23.89 r 6.01
25 (15-30)
23.89 r 6.01
25 (15-35)
25.56 r 8.46
25 (15-45)
61.11 r 19.33
60 (30-85)
 ACI-P 19.29 r 8.86
20 (5-30)
22.86 r 6.36
20 (15-35)
22.86 r 9.51
20 (10-40)
78.57 r 12.82
75 (65-95)
 P value at each time point 
  (MACI:ACI-P)
.301 .658 .380 .049
Social role functioning T0:T1 P = .108
T0:T2 P = .416
T0:T3 P = .027
T1:T2 P = .109
T1:T3 P = .141
T2:T3 P = .066
T0:T1 P = .078
T0:T2 P = .206
T0:T3 P = .039
T1:T2 P t .999
T1:T3 P = .414
T2:T3 P = .655
 MACI 70.83 r 34.23
75 (12.5-112.5)
97.22 r 20.52
112.5 (62.5-112.5)
84.72 r 31.11
100 (37.5-112.5)
106.94 r 9.08
112.5 (87.5-112.5)
 ACI-P 85.71 r 30.13
87.5 (25-112.5)
103.57 r 15.67
112.5 (75-112.5)
103.57 r 15.67
112.5 (75-112.5)
107.14 r 9.83
112.5 (87.5-112.5)
 P value at each time point 
  (MACI:ACI-P)
.335 .464 .179 .897
Emotional role functioning T0:T1 P = .180
T0:T2 P = .785
T0:T3 P = .276
T1:T2 P = .317
T1:T3 P t .999
T2:T3 P = .414
T0:T1 P = .317
T0:T2 P = .785
T0:T3 P = .655
T1:T2 P = .180
T1:T3 P = .317
T2:T3 P = .317
 MACI 77.78 r 44.10
100 (0-100)
92.59 r 22.23
100 (33.3-100)
81.48 r 37.68
100 (0-100)
92.59 r 22.22
100 (33.3-100)
 ACI-P 90.47 r 25.21
100 (33.3-100)
100 r 0
100 (100)
85.71 r 26.23
100 (33.3-100)
95.24 r 12.60
100 (66.67-100)
 P value at each time point 
  (MACI:ACI-P)
.586 .378 .944 .927
(continued)
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MRI Evaluation
All patients underwent MRI evaluation at the final follow-
up to determine the morphological status of the cartilage
as described by the MOCART score. Further, the dGEM-
RIC technique was used to evaluate alterations of the T1
relaxation time of the repair cartilage and hence the con-
tent of glycosaminoglycans. Overall result and distribution
in subdomains of the MOCART score are shown in Table 5.
In the majority of the patients (10/16; MACI, n = 5; ACI-
P, n = 5), a complete defect filling was present. One patient
in the ACI-P group displayed hypertrophy of the repair tis-
sue, which represents 6% of the whole study group and
14.3% of the ACI-P group. Further, 4 patients (MACI,
n = 3; ACI-P, n = 1) had exposed subchondral bone. The
repair tissue was inhomogeneous in 10 patients (MACI,
n = 6; ACI-P, n = 4). In 15 patients (MACI, n = 8; ACI-P,
n = 7) alterations of the subchondral bone were present.
Cystic lesions were present in 5 patients (MACI, n = 2;
ACI-P, n = 3) and adhesions and synovitis in another 5
patients (MACI, n = 1; ACI-P, n = 4).
The dGEMRIC analyses revealed a mean reduction of
the T1 relaxation times after contrast of 174.6 6 152.8
milliseconds (MACI, –237.4 6 125.7 ms; ACI-P, –93.9 6
154.2 ms) in the repair tissue compared with the normal
cartilage (Table 6).
We found that 8 patients (MACI, n = 6; ACI-P, n = 2)
had a reduction of more than 200 milliseconds, 1 patient
in the MACI group had only a slight reduction (–13 ms),
and 2 patients in the ACI-P group had higher T1 values
(80 and 93 ms, respectively). Figure 1 presents examples
of dGEMRIC analysis in the repair tissue in 2 patients in
the final follow-up after MACI and ACI-P, respectively.
Lower dGEMRIC values were present in the repair tis-
sue compared with the normal adjacent cartilage in both
techniques; however, we found similar values when
comparing the 2 methods. This can be interpreted as
incomplete healing with persistent reduction of the glycos-
aminoglycan content in the repair tissue in the long-term
course. According to the MOCART score and dGEMRIC,
no significant differences were found between the 2 groups.
Complications and Failures
As evaluated at the final follow-up by MRI, no patient in
the MACI group and only 1 patient in the ACI-P group
showed graft hypertrophy, although this patient did not
receive further surgery. There were 3 patients (33.3%) in
MACI and 2 patients (28.6%) in ACI-P who underwent fur-
ther surgery until the last follow-up. We noted that 1
patient in the MACI group required an early arthroscopy
(9 months after ACI) because of symptomatic hypertrophy.
A further 2 MACI patients received arthroscopic surgery
after 3 years due to pain and cartilage thinning. The 2
patients in the ACI-P group received arthroscopic synovec-
tomy at 2 years and at 7 years after ACI. None of the
patients had joint infections, postoperative fever or infec-
tion, arterial injuries, or nerve damage. None of the
patients had received joint replacement surgery.
DISCUSSION
The highest but yet unreached goal in the treatment of
articular cartilage lesions is to generate substitute carti-
lage with the same biomechanical and biochemical proper-
ties of hyaline cartilage. Even though third-generation ACI
is considered to present the highest treatment standard,
the superiority of this advancement is not well-supported
by clinical studies, and few studies have addressed
whether higher generation ACI results in superior clinical
outcome.2,3,10,20,24,27,40
To the best of our knowledge, this is the first randomized
controlled trial with a follow-up of almost 10 years comparing
the original technique (ACI-P) with the third-generation
technique (MACI). Interpretation of our data has to be
Mental health T0:T1 P = .887
T0:T2 P t .999
T0:T3 P = .725
T1:T2 P t .999
T1:T3 P = .623
T2:T3 P = .717
T0:T1 P = .141
T0:T2 P = .932
T0:T3 P = .149
T1:T2 P = .340
T1:T3 P = .394
T2:T3 P = .206
 MACI 54.67 r 5.29
56 (48-64)
53.78 r 6.96
52 (44-64)
54.67 r 5.66
52 (48-64)
52.89 r 10.73
52 (40-68)
 ACI-P 55.43 r 5.38
56 (48-60)
59.43 r 4.28
60 (56-68)
52.57 r 14.86
56 (20-64)
62.86 r 10.76
64 (44-76)
 P value at each time point 
  (MACI:ACI-P)
.662 .103 .553 .087
aScores are presented as mean r SD with median (range). ACI-P, autologous chondrocyte implantation with periosteum; MACI, matrix-
associated autologous chondrocyte implantation. Friedman, Wilcoxon matched-pairs, and Mann-Whitney U tests were used. Boldface satis-
tical significance at P < .05. 
bStatistical assessments that remained significant after Bonferroni correction. 
TABLE 4
(continued)
Preoperative  
(T0)
(n = 16)
12 Months 
Postoperative (T1)
(n = 16)
24 Months 
Postoperative 
(T2)
(n = 16)
Last Follow-up (T3)
(n = 16)
P Value 
(MACI)
P Value  
(ACI-P)
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performed with caution due to the small sample size, which
was further limited by a loss to follow-up of 24%.
Our data confirm that early improvement after ACI is
sustained for a long period, as shown by the significant
improvement in almost all outcome parameters, which per-
sisted until the final follow-up. Considering the ACI-P
group, our results are in accordance with previous publica-
tions with long-term follow-up.23,26,29,33 Ogura et al29 pro-
vided a sufficient survival rate for the treatment of large
cartilage lesions up to 20 years after ACI-P. Those
investigators showed that the greatest improvement in
clinical scores occurred during the first 2 years. Peterson
et al33 reported that 92% of 224 patients had a satisfactory
result in a study evaluating ACI-P after a mean follow-up
of 12.8 years. In another study by our group, we evaluated
23 patients after first-generation ACI-P with a mean
follow-up of almost 10 years, showing substantial improve-
ment in all clinical outcome parameters, although a small
deterioration was found between the intermediate and
final evaluations.23 Interestingly, no deterioration was
TABLE 5
Magnetic Resonance Observation of Cartilage Repair (MOCART) Score at the Last Follow-upa
MACI (n = 9) ACI-P (n = 7) P Value
Defect repair filling .425 (Wilcoxon matched-pairs and
Mann-Whitney U tests)
Complete (on a level with adjacent cartilage) 5 (55.5) 5 (71.4)
Hypertrophy (over the level of the adjacent cartilage) 0 (0) 1 (14.3)
Incomplete .50% of the adjacent cartilage 0 (0) 0 (0)
Incomplete\50% of the adjacent cartilage 1 (11.1) 0 (0)
Subchondral bone exposed 3 (33.4) 1 (14.3)
Integration .206 (Wilcoxon matched-pairs and
Mann-Whitney U tests)
Complete integration with adjacent cartilage 2 (22.2) 3 (42.8)
Incomplete integration (demarcating border visible) 2 (22.2) 2 (28.6)
Defect visible\50% of the length of the repair tissue 3 (33.4) 2 (28.6)
Defect visible .50% of the length of the repair tissue 2 (22.2) 0 (0)
Structure .696 (x2 test)
Homogeneous 3 (33.4) 3 (42.8)
Inhomogeneous or cleft formation 6 (66.6) 4 (57.2)
Surface .217 (Wilcoxon matched-pairs and
Mann-Whitney U tests)
Surface intact (lamina splendens intact) 2 (22.2) 3 (42.8)
Surface damaged\50% of repair tissue depth 3 (33.4) 3 (42.8)
Surface damaged .50% of repair tissue depth 4 (44.4) 1 (14.3)
Signal proton density weighted mode .193 (Wilcoxon matched-pairs and
Mann-Whitney U tests)
Isointense 5 (55.5) 6 (85.7)
Moderately hyperintense 3 (33.4) 1 (14.3)
Markedly hyperintense 1 (11.1) 0 (0)
Subchondral lamina .849 (x2 test)
Intact 8 (88.9) 6 (85.7)
Not intact 1 (11.1) 1 (14.3)
Subchondral bone .362 (x2 test)
Intact 1 (11.1) 0 (0)
Not intact (edema, cyst) 8 (88.9) 7 (100)
Signal T1 .999 (Mann-Whitney U test)
Isointense 9 (100) 7 (100)
Moderately hyperintense 0 (0) 0 (0)
Markedly hyperintense 0 (0) 0 (0)
Adhesions .146 (x2 test)
No 8 (88.9) 4 (57.2)
Yes 1 (11.1) 3 (42.8)
Effusion .771 (x2 test)
No 7 (77.7) 5 (71.4)
Yes 2 (22.2) 2 (28.6)
Mean MOCART score 58.9 6 18.3 71.4 6 19.3 .206 (t test)
aAbsolute numbers (percentages) are presented for categorical data of the MOCART subscores at the last follow-up (T3). A lower MOCART
score corresponds to more normal magnetic resonance imaging diagnostic findings. MACI, matrix-associated autologous chondrocyte
implantation; ACI-P, autologous chondrocyte implantation with periosteum. Unpaired t test, Wilcoxon matched-pairs test, Mann-Whitney
U test, and x2 test were used. P\ .05 was considered significant.
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found in the ACI-P group of this study between the inter-
mediate and final evaluation time point.
Compared with the well-documented clinical improve-
ment after ACI-P,23,26,29,33 substantial knowledge about
the long-term progression of MACI is still rare.1,8,16 Aldrian
et al1 evaluated 16 patients treated with MACI with a 10-
year follow-up, showing significant improvement in all clin-
ical scores. Kreuz et al16 described 21 patients who had
received MACI and experienced significant improvement
of IKDC and Lysholm scores 12 years postoperatively. In
2016, Gille et al8 evaluated 14 patients with a mean
follow-up of 15 years, reporting significant improvement in
all assessed scores after MACI. All 3 of these studies lacked
any comparative cohort or control group.
In our clinical evaluation, the MACI group showed no sig-
nificant improvement in daily knee functionality (Lysholm
score) and sports activity (Tegner Activity Score), which is
different from the results for the ACI-P group and could be
due to higher baseline scores in this group. However,
MACI showed significant long-lasting improvements in sub-
jective IKDC and SF-36 physical health scores. The compar-
ison between both groups revealed that only the vitality
subscale of SF-36 at the final evaluation time point showed
significantly higher scores for ACI-P. Our findings are consis-
tent with the limited number of studies published on the
comparison between different generations of ACI2,3,20,24 or
comparison of ACI with other techniques such as
microfracture.14 The largest retrospective study was pub-
lished by Nawaz et al,24 who evaluated the functional out-
come of 827 patients who received either ACI with
Chondron and periosteum (ACI-C/ACI-P) or MACI. No differ-
ences were found between the survival rates of the ACI-C/
ACI-P and MACI techniques after 10 years of follow-up.
The only study showing better results for higher gener-
ation ACI was published by Niemeyer et al.27 In
a matched-pair analysis in 46 patients with 10 years of
follow-up, those investigators found significantly better
functional outcomes in the patients who underwent
second-generation ACI compared with ACI-P.
Even though clinical results are the primary outcome
criterion, it is of utmost interest to analyze the biological
features of the cartilage repair tissue after ACI.31 Because
histological evaluation is not conducted in routine follow-
up, MRI assessment is considered the most effective nonin-
vasive tool to evaluate the internal structures of the knee.
We conductedMRI assessment by applying amorphological
graft scoring system (MOCART) and dGEMRIC, which
provides information regarding the histological quality of
the repair tissue. MRI evaluation at the final follow-up
showed a complete defect filling in 55.6% and 71.4% of
MACI and ACI-P patients, respectively. This is in line
with the study by Kreuz et al,16 who reported complete
defect filling of 57.1% of patients who underwent MACI.
In the study by Aldrian et al,1 the majority of patients
who underwent MACI developed good-quality repair tissue
on imaging, showing complete integration of the graft at
the early follow-up, which was maintained until 5 years
after surgery and followed by a gradual degradation. After
10 years of follow-up, the mean MOCART score of their
patients was 70.4 6 16.1. Their results are comparable
with our patients who received ACI-P (71.4 6 19.3). Man-
fredini et al20 did not find any significant differences
between patients who underwent ACI-P (Carticel tech-
nique) and patients who had arthroscopic MACI based on
a hyaluronan scaffold (Hyalograft C).
In this study, we further provide data on the composi-
tion of the cartilage assessed by dGEMRIC. Our data indi-
cate higher quality of the transplant and cartilage in ACI-P
patients. Reports on dGEMRIC for the postoperative eval-
uation of cartilage repair are scarce and have provided con-
troversial results.8,37 Vasiliadis et al37 found no correlation
between dGEMRIC and clinical scores in a study evaluat-
ing 31 patients who underwent ACI-P surgery with 9 years
of follow-up. Those investigators reported that the
TABLE 6
Delayed Gadolinium-Enhanced Magnetic Resonance Imaging of Cartilage Data at the Last Follow-upa
Post T1 Repair Site Post T1 Normal Cartilage Post T1 Difference
MACI (n = 9) 557.7 6 123.2
532 (421.3 to 741.4)
795.1 6 57
823.6 (693 to 849.1)
–237.4 6 125.7
–293 (–380.4 to –13.2)
ACI-P (n = 7) 709.6 6 165.6
732 (419.9 to 894.4)
803.5 6 46.8
802.3 (737.2 to 874.3)
–93.9 6 154.2
–83 (–338 to 93.2)
P value .563 .344 .857
aValues are presented in milliseconds as mean 6 SD with median (range). Unpaired t test was used. P\.05 was considered significant. ACI-P,
autologous chondrocyte implantation with periosteum; MACI, matrix-associated autologous chondrocyte implantation; T1, T1 relaxation time.
Figure 1. Representative examples of dGEMRIC analysis in
the repair tissue are shown for (A) autologous chondrocyte
implantation with a periosteum cover (ACI-P) and (B)
matrix-associated autologous chondrocyte implantation
(MACI). dGEMRIC, delayed gadolinium-enhanced magnetic
resonance imaging of cartilage.
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cartilage defect area was restored in most of the cases, and
the quality of the repair tissue was identical to the sur-
rounding cartilage.
The clinical data presented in the current prospective ran-
domized trial seem to indicate that ACI-P provides equal if
not better results than MACI. When critically reviewed,
this finding is in accordance with the available literature.
The MRI evaluation looking at morphological features and
quality of the repair tissue did not show significant differen-
ces between ACI-P and MACI; any differences found favored
the ACI-P group. This raises the question why higher gener-
ation ACI is considered the method of choice and thought to
present a higher treatment standard. This might be due to
practical advantages of MACI, such as shorter operation
time and no need for an additional incision. Further, MACI
is more appliable to difficult locations in the joint than is
ACI-P, and cells are thought to remain in place and more
equally distributed.35 Some studies have reported high revi-
sion rates due to graft hypertrophy or adhesions after
ACI-P.26,27 In our study, graft hypertrophy was found in
only 1 patient in ACI-P group at the last follow-up by MRI.
This presents a hypertrophy rate of 6% for the total sample
and 14.3% in the ACI-P group. It remains unknown at this
stage why the modifications of ACI do not result in superior
morphological repair tissue. One explanation might be the
chondrogenic potential of periosteum, by providing either
growth factors or mesenchymal stem cells.28,32 Collagen
fleece or matrices lack this additional effect, and their pres-
ence in the cartilage defect might even be suppressive for car-
tilage growth.
The main weakness of this randomized clinical trial is
that it is underpowered, which limits the detection of con-
founding factors, correlation, and subgroup analysis. Fur-
ther, the randomization method was not stratified by sex
and left the ACI-P group with only male patients. The
results of this investigation should be tested by performing
a randomized clinical trial stratified by sex and age with
a larger sample size.
CONCLUSION
The long-term results of this randomized clinical trial con-
firm that first- and third-generation ACIs are equally effec-
tive for the treatment of cartilage defects in the femoral
condyle. Even though superiority of one method over the
other was not evident, a tendency toward more reliable
clinical and radiological improvements was found in ACI-
P versus MACI. Taken together, there is still no sufficient
evidence to show any superiority of one ACI generation
over the other, and further trials, particularly studies aim-
ing to evaluate the long-term follow-up of different gener-
ations of ACI, are necessary.
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